A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial

NCT00890734 Phase 2 COMPLETED

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Details

Lead sponsor	Cytos Biotechnology AG
Phase	Phase 2
Status	COMPLETED
Enrolment	63
Start date	2009-04
Completion	2010-11

Conditions

• Allergic Bronchial Asthma

Interventions

• CYT003-QbG10
• Placebo

Primary outcomes

• Markers for inflammation and asthma — 1-3 months

Countries

Germany